CA2672155C - Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases - Google Patents

Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases Download PDF

Info

Publication number
CA2672155C
CA2672155C CA2672155A CA2672155A CA2672155C CA 2672155 C CA2672155 C CA 2672155C CA 2672155 A CA2672155 A CA 2672155A CA 2672155 A CA2672155 A CA 2672155A CA 2672155 C CA2672155 C CA 2672155C
Authority
CA
Canada
Prior art keywords
body weight
xanthohumol
active substance
use according
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2672155A
Other languages
English (en)
French (fr)
Other versions
CA2672155A1 (en
Inventor
Claus Hellerbrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flaxan GmbH and Co KG
Original Assignee
Flaxan GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flaxan GmbH and Co KG filed Critical Flaxan GmbH and Co KG
Publication of CA2672155A1 publication Critical patent/CA2672155A1/en
Application granted granted Critical
Publication of CA2672155C publication Critical patent/CA2672155C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2672155A 2006-12-22 2007-12-21 Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases Expired - Fee Related CA2672155C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006062264A DE102006062264A1 (de) 2006-12-22 2006-12-22 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
DE102006062264.2 2006-12-22
PCT/EP2007/011358 WO2008077618A1 (de) 2006-12-22 2007-12-21 Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen

Publications (2)

Publication Number Publication Date
CA2672155A1 CA2672155A1 (en) 2008-07-03
CA2672155C true CA2672155C (en) 2013-10-01

Family

ID=39186950

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2672155A Expired - Fee Related CA2672155C (en) 2006-12-22 2007-12-21 Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases

Country Status (7)

Country Link
US (1) US20100029757A1 (enExample)
EP (1) EP2120906B1 (enExample)
JP (1) JP5513126B2 (enExample)
CA (1) CA2672155C (enExample)
DE (1) DE102006062264A1 (enExample)
RU (1) RU2454996C2 (enExample)
WO (1) WO2008077618A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
ES2441665T3 (es) * 2009-11-26 2014-02-05 Genfit Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
EP2861202B1 (en) 2012-06-18 2018-07-18 3M Innovative Properties Company Powder composition for air polishing the surface of hard dental tissue
HUE052388T2 (hu) 2012-07-26 2021-04-28 Arcaini Antonio Pörkölt kivonatot és xantohumolt tartalmazó kompozíciók alkalmazásai
EP2742898A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Powder jet device for dispensing a dental material
WO2014099490A2 (en) 2012-12-17 2014-06-26 3M Innovative Properties Company Device for dispensing a dental material with locking mechanism
EP2742897A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Nozzle head, hand piece and powder jet device for applying a dental material
WO2017001020A1 (de) 2015-07-02 2017-01-05 Flaxan Gmbh & Co. Kg Substanz auf hopfenbasis sowie verwendung der substanz
AU2017384173A1 (en) * 2016-12-20 2019-06-27 Suntory Holdings Limited Lipid metabolism-promoting composition including isoxanthohumol
CA3148455A1 (en) 2017-07-11 2019-01-17 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
US11786484B2 (en) 2018-07-11 2023-10-17 Aquanova Ag Xanthohumol solubilizate
EP3820527B1 (de) * 2018-07-11 2023-08-23 Aquanova AG Xanthohumol-solubilisat
US20210186924A1 (en) * 2018-08-10 2021-06-24 Suntory Holdings Limited Composition for promoting uric acid excretion, composition for inhibiting urat1 and composition for lowering blood uric acid level
JPWO2020031953A1 (ja) * 2018-08-10 2021-08-10 サントリーホールディングス株式会社 微生物増殖抑制剤、微生物汚染防止方法、及び、飲料
CN112566515A (zh) * 2018-08-10 2021-03-26 三得利控股株式会社 肠内环境改善用组合物及肠内菌丛的改善方法
US20210161857A1 (en) * 2018-08-10 2021-06-03 Suntory Holdings Limited Composition and method for suppressing increase in blood glucose level
EP4291307A4 (en) * 2021-02-09 2025-01-22 Oregon State University Xanthohumol derivatives and methods for making and using
AU2022308043A1 (en) * 2021-07-09 2024-01-25 INNOX Corp. Prenylated chalcone and flavonoid compositions for use in treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07285856A (ja) * 1994-04-21 1995-10-31 Hoechst Japan Ltd 骨粗鬆症治療剤
KR100594400B1 (ko) * 1996-08-30 2006-07-03 엔피에스 파마슈티칼즈, 인코포레이티드 이소발레린산 유도체 ｃｎｓ 억제제를 이용한 경련, 경직의 치료
JP2003504327A (ja) 1999-07-08 2003-02-04 プレンダーガスト、パトリック、ティ． 感染症の治療を目的としたフラボン類、クマリン類および関連化合物の使用
JP3293601B2 (ja) * 1999-09-03 2002-06-17 松下電器産業株式会社 管球およびその製造方法
US20040002423A1 (en) * 2000-04-10 2004-01-01 Hiromu Ohnogi Remedies
BR0208418A (pt) * 2001-04-05 2004-03-30 Unilever Nv Uso de isoxantohumol e/ou xantohumol, método para administrar isoxantohumol e/ou xantohumol a seres humanos em necessidade de receber um componente ani-inflamatório ou anti-envelhecimento, e, produto alimentìcio
JPWO2003006037A1 (ja) * 2001-07-13 2004-10-28 タカラバイオ株式会社 治療剤
DE10308864B4 (de) 2003-02-28 2007-03-01 Paulaner Brauerei Gmbh & Co. Kg Neues Brauverfahren, damit gebrautes Bier und dessen Verwendung
EP1543834A1 (en) 2003-12-16 2005-06-22 Biodynamics Production of hop extracts having oestrogenic and antiproliferative bioactivity
WO2006099015A2 (en) 2005-03-09 2006-09-21 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤
WO2007016578A2 (en) * 2005-07-29 2007-02-08 Bioactives, Inc. Prenylflavonoid formulations
CA2618613A1 (en) * 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤

Also Published As

Publication number Publication date
RU2454996C2 (ru) 2012-07-10
CA2672155A1 (en) 2008-07-03
JP2010513360A (ja) 2010-04-30
EP2120906B1 (de) 2015-04-22
WO2008077618A1 (de) 2008-07-03
JP5513126B2 (ja) 2014-06-04
DE102006062264A1 (de) 2008-06-26
RU2009128213A (ru) 2011-01-27
US20100029757A1 (en) 2010-02-04
EP2120906A1 (de) 2009-11-25

Similar Documents

Publication Publication Date Title
CA2672155C (en) Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases
CN101278928A (zh) 含左卡尼汀或其衍生物的药物组合物及其用途
KR100404303B1 (ko) 올티프라즈의 간섬유화 및 간경화 진행의 예방 및치료제로서의 용도 및 올티프라즈를 주성분으로 함유하는제약 조성물
EP3391893B1 (en) Pharmaceutical composition for treating leukemia and preparation method thereof
JP2005239581A (ja) 心筋炎の予防、治療又は改善用組成物
KR102187951B1 (ko) 녹각 영지버섯 추출물 및 퀘르세틴을 유효성분으로 포함하는 엡스타인 바 바이러스-양성 위암 치료용 약학적 조성물
JP2004091473A (ja) 色素沈着改善治療薬
CN102292081B (zh) 包含硫辛酸和羟基柠檬酸作为活性成分的药物联用物
US20140066519A1 (en) Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases
EP1263435B1 (en) Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
EP0722325A1 (fr) Composition pour le traitement ou la prevention de l'herpes
JP2018519342A (ja) ホップに基づく物質およびその物質の使用
CN106822152B (zh) 一种药物组合物及其应用
KR20060066177A (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 간기능 치료제 조성물
JP2001335503A (ja) ラジカル消去用医薬品
KR100377789B1 (ko) 간섬유화 및 간경화 치료 및 예방용 의약 조성물
CN102076346A (zh) 一种人用药物组合物及铋或锌剂的制备
KR100473078B1 (ko) 예덕나무피엑스를유효성분으로하는간기능개선제
Kashyap et al. Molecular Aspects on Anti-SARS-CoV-2 Activity of Flavonols: Inhibitory on Protein Targets, Immunomodulatory, and Anti-Inflammatory Effects
TWI624264B (zh) 南洋山蘇水萃物的用途
KR20230080579A (ko) 질레우톤(zileuton)을 유효성분으로 포함하는 피부 방사선 증후군 예방 또는 치료용 약학 조성물
CN101194900A (zh) 桂皮醛在α-葡萄糖苷酶抑制剂中的应用
EP2958627A1 (en) Composition for the treatment of metabolic disorders
CN114377005A (zh) 泽兰黄酮在制备抗高尿酸血症和抗痛风药物中的应用
WO2019216832A1 (en) Composition for oral administration comprising one or more cannabinoids

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181221